Peringatan Keamanan

There are no data regarding overdosage with tralokinumab. In clinical trials, intravenous doses up to 30 mg/kg and subcutaneous doses of 600mg every two weeks for 3 months were found to be well-tolerated.L39282 In the event of a suspected overdose, patients should be administered supportive care as clinically indicated.

Tralokinumab

DB12169

biotech approved investigational

Deskripsi

Atopic dermatitis (AD) is an inflammatory skin disorder that causes skin inflammation, skin barrier dysfunction, and chronic pruritus.A242432 It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis. While AD is a heterogenous condition with a variety of apparent genetic and environmental causes,A242422 it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13).A242427

Tralokinumab is a fully human IgG4 monoclonal antibody targeted against IL-13. It neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms. Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the US in December 2021.L39287,L39558

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life of tralokinumab is approximately 22 days.[L39287]
Volume Distribusi The volume of distribution of tralokinumab as estimated by population pharmacokinetic analysis was 4.2 L.[L39287]
Klirens (Clearance) The clearance of tralokinumab following subcutaneous administration was estimated to be 0.149 L/day.[L39282]

Absorpsi

The absolute bioavailability of tralokinumab following subcutaneous administration is 76%, with a median Tmax of 5-8 days.L39287 In clinical trials, steady-state serum concentrations were achieved by week 16 of treatment, with trough concentrations ranging from 98.0±41.1 mcg/mL to 101.4±42.7 mcg/mL.L39287

Metabolisme

As with other therapeutic and endogenous proteins, the metabolism of tralokinumab is likely to occur via catabolism to smaller peptides and amino acids and has not been studied directly.L39287

Rute Eliminasi

The elimination of tralokinumab occurs through a non-saturable proteolytic pathway.L39287

Interaksi Obat

372 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Tralokinumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Tralokinumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Tralokinumab.
Estrone Estrone may increase the thrombogenic activities of Tralokinumab.
Estradiol Estradiol may increase the thrombogenic activities of Tralokinumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Tralokinumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Tralokinumab.
Mestranol Mestranol may increase the thrombogenic activities of Tralokinumab.
Estriol Estriol may increase the thrombogenic activities of Tralokinumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Tralokinumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Tralokinumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Tralokinumab.
Tibolone Tibolone may increase the thrombogenic activities of Tralokinumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Tralokinumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Tralokinumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Tralokinumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Tralokinumab.
Zeranol Zeranol may increase the thrombogenic activities of Tralokinumab.
Equol Equol may increase the thrombogenic activities of Tralokinumab.
Promestriene Promestriene may increase the thrombogenic activities of Tralokinumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Tralokinumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Tralokinumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Tralokinumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Tralokinumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Tralokinumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Tralokinumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Tralokinumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Tralokinumab.
Formononetin Formononetin may increase the thrombogenic activities of Tralokinumab.
Estetrol Estetrol may increase the thrombogenic activities of Tralokinumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tralokinumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tralokinumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tralokinumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Tralokinumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Tralokinumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tralokinumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tralokinumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Tralokinumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tralokinumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Tralokinumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Tralokinumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Tralokinumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tralokinumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tralokinumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Tralokinumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tralokinumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tralokinumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Tralokinumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tralokinumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Tralokinumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Tralokinumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Tralokinumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tralokinumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tralokinumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Tralokinumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Tralokinumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Tralokinumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Tralokinumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Tralokinumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Tralokinumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Tralokinumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Tralokinumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Tralokinumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Tralokinumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Tralokinumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Tralokinumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Tralokinumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Tralokinumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Tralokinumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Tralokinumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Tralokinumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Tralokinumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Tralokinumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Tralokinumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Tralokinumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Tralokinumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Tralokinumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Tralokinumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Tralokinumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Tralokinumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Tralokinumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Tralokinumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Tralokinumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Tralokinumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Tralokinumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Tralokinumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Tralokinumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tralokinumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Tralokinumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Tralokinumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Tralokinumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Tralokinumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Tralokinumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Tralokinumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Tralokinumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Tralokinumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tralokinumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Tralokinumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Tralokinumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Tralokinumab.

Target Protein

Interleukin-13 IL13

Referensi & Sumber

Artikel (PubMed)
  • PMID: 33459118
    Kaplon H, Reichert JM: Antibodies to watch in 2021. MAbs. 2021 Jan-Dec;13(1):1860476. doi: 10.1080/19420862.2020.1860476.
  • PMID: 29906525
    Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, Moate R, van der Merwe R: Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019 Jan;143(1):135-141. doi: 10.1016/j.jaci.2018.05.029. Epub 2018 Jun 12.
  • PMID: 30641038
    Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, Szymczak S, Swindell WR, Sarkar MK, Raja K, Shao S, Patrick M, Gao Y, Uppala R, Perez White BE, Getsios S, Harms PW, Maverakis E, Elder JT, Franke A, Gudjonsson JE, Weidinger S: Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019 Jul;139(7):1480-1489. doi: 10.1016/j.jid.2018.12.018. Epub 2019 Jan 11.
  • PMID: 31509236
    Furue K, Ito T, Tsuji G, Ulzii D, Vu YH, Kido-Nakahara M, Nakahara T, Furue M: The IL-13-OVOL1-FLG axis in atopic dermatitis. Immunology. 2019 Dec;158(4):281-286. doi: 10.1111/imm.13120. Epub 2019 Oct 1.

Contoh Produk & Brand

Produk: 9 • International brands: 0
Produk
  • Adbry
    Injection, solution • 150 mg/1mL • Subcutaneous • US • Approved
  • Adbry
    Injection, solution • 300 mg/2mL • Subcutaneous • US • Approved
  • Adtralza
    Injection, solution • 150 mg • Subcutaneous • EU • Approved
  • Adtralza
    Injection, solution • 150 mg • Subcutaneous • EU • Approved
  • Adtralza
    Injection, solution • 150 mg • Subcutaneous • EU • Approved
  • Adtralza
    Injection, solution • 300 mg • Subcutaneous • EU • Approved
  • Adtralza
    Injection, solution • 300 mg • Subcutaneous • EU • Approved
  • Adtralza
    Solution • 150 mg / mL • Subcutaneous • Canada • Approved
Menampilkan 8 dari 9 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul